01 Increasing Prevalence of Acne among Teens and Young Adults Teens and young adults undergo hormonal imbalances in their lifespan's adolescent and post-adolescent stages. It is a common medical condition that occurs among people following different cultures, traditions, and lifestyles. Acne can also spread faster in the population because of certain medications, bad diets, and stress. These factors lead to excess oil production that is clogged in hair follicles. The clogged oil is infected by bacteria, further causing inflammation. In addition, the rising occurrence of a severe type of acne, such as cystic acne, is advancing the demand for isotretinoin drugs.Another factor reported as the cause of acne was the individual's genetic makeup. According to the survey conducted by the European Academy of Dermatology and Venereology, the individuals affected by acne preferred topical creams for treatment. This factor creates opportunities for market players to develop new isotretinoin topical creams and lotions.
02 Rising Incidence of Neuroblastoma Increasing cases of neuroblastoma among adolescents drive the demand for isotretinoin drugs. The prevalence of neuroblastoma is surging due to demographic or environmental factors. However, isotretinoin is used in neuroblastoma chemotherapy sessions as it contains a retinoid that acts upon the cell nucleus, further inhibiting cell growth. Since neuroblastoma has fatal consequences if untreated, market firms are pouring a lot of money into R&D operations to create novel formulations.Furthermore, the market players are working on the different compositions of isotretinoin with components such as aldesleukin, dinutuximab, vorinostat, and sargramostim to enhance the efficacy and effectiveness of the drug. Monoclonal antibodies, such as dinutuximab, constitute tumor growth-blocking properties that prevent neuroblastoma cells in diagnosed adolescents and children. Such strategies are assessed to raise market demand in the projected period.
01 Concerns Pertaining to Drug Side Effects The use of isotretinoin medication during pregnancy poses health risks. The drug can cause several congenital disabilities, such as cleft palate and heart defects. Other complications hindering the isotretinoin drugs market include dry skin, severely chapped lips, nosebleeds, dry and irritated eyes, and dry mouth. Additionally, the medication was reported to cause temporary side effects such as worsening acne, night blindness, thinning hair, and muscle or joint pain. The potential long-term side effects of isotretinoin drugs include erectile dysfunction, genital numbness, and loss of libido. The medication was also reported to cause depression, psychosis, suicidal thoughts, neurological problems, and internal organ damage. Such factors are expected to hamper the market growth over the forecast period.
01 Introduction of New Micronized Formulation for Severe Recalcitrant Nodular Acne Treatment Isotretinoin drug is known to treat severe nodular acne. Introducing micronized formulated drugs provides an extra edge to patients suffering from severe recalcitrant nodular acne problems. The new micronized formulation shows improved bioavailability with negligible food effects. The formulation is safe with a lower risk of mucocutaneous events and hypertriglyceridemia. Moreover, the minimal risk factors allow market players to formulate new drugs.Additionally, the industry players are developing newly acquired micronized isotretinoin-based oral therapy to treat nodular acne. For instance, in January 2019, Almirall LLC launched Seysaratm (Sarecycline) to treat acne vulgaris with varying levels of inflammation ranging from moderate to severe medical conditions. Likewise, in February 2020, Sun Pharma introduced Absorica LD capsules in the US with micronization technology to treat severe recalcitrant nodular acne. The newly formulated drug optimizes absorption at a lower dose with a higher level of efficacy and safety. The improved version of isotretinoin drugs with higher efficiency is expected to create new possibilities for industry providers.
February 2026 Zydus Lifesciences expanded its dermatology-focused pharmaceutical portfolio by strengthening commercialization efforts for its isotretinoin capsule products in international markets. The company continued improving availability of generic isotretinoin formulations used in the treatment of severe acne, supporting broader access to dermatological therapies.
January 2026 Pharmaceutical companies continued advancing generic isotretinoin supply and distribution networks across global markets as demand increased for cost-effective acne treatment options. Manufacturers focused on maintaining regulatory compliance, improving accessibility, and expanding dermatology product portfolios.
November 2025 Indian pharmaceutical manufacturers expanded their dermatology portfolios by strengthening production and commercialization activities for isotretinoin-based formulations. Companies continued focusing on affordable generic alternatives to branded isotretinoin products to support acne treatment accessibility in emerging markets.
September 2025 Dermatology-focused pharmaceutical companies continued investing in advanced formulation approaches for isotretinoin products, including improved bioavailability and patient-friendly dosage formats. Innovation efforts remained focused on enhancing treatment convenience and supporting better patient adherence for severe acne management.